Earnings Ahead

THTX - Theratechnologies

2.35 -0.13 -5.24

Theratechnologies

Theratechnologies

About

Profile


Headquarters

Montreal, Canada


Intraday

High
-
Low
-

52-week

High
-
Low
-

THTX



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Theratechnologies reports Q4 earnings miss; initiates FY23 outlook
  • Theratechnologies slumps 30% as cancer drug trial enrollment paused on efficacy, safety woes
  • Theratechnologies reports Q3 results, FY22 guidance on track
  • Theratechnologies stock rises 9% on positive data from early-stage trial data of cancer therapy
  • Theratechnologies revenue of $19.27M misses by $0.86M, tightens FY2022 revenue outlook
  • Theratechnologies stock gains on securing $100M term loan
  • Theratechnologies begin enrollment in early-stage study of TH1902 in advanced cancers
  • Theratechnologies reports Q1 results
  • Theratechnologies GAAP EPS of -$0.34 misses by $0.26, revenue of $18.75M misses by $1.73M
  • Theratechnologies net loss widens in Q3
  • Theratechnologies EPS misses by $0.03, misses on revenue
  • Theratechnologies reports positive results for Trogarzo IV push administration study
  • Theratechnologies EPS in-line, misses on revenue
  • Theratechnologies adds Frank Holler to board
  • Theratechnologies reports Trogarzo results at ACTHIV 2021 meeting
  • Theratechnologies EPS misses by $0.03, misses on revenue
  • Dosing underway in Theratechnologies early-stage study of TH1902 in SORT1+ solid tumors
  • Theratechnologies EPS in-line, beats on revenue
  • Theratechnologies surges after fast track designation from FDA
  • Theratechnologies launches $40M bought-deal offering